NCCN Guideline update: Breast Cancer Version 1.2004.
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D000077289:Letrozole; D008198:Lymph Nodes / Q000528:radiation effects; D008207:Lymphatic Metastasis; D008408:Mastectomy; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism / Q000628:therapy*; D009570:Nitriles / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole